Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by harposon Feb 06, 2017 7:31pm
193 Views
Post# 25807491

I differ slightly with Bencro on buyout scenarios

I differ slightly with Bencro on buyout scenarios No question JV would be best for us and the tech. However, if a big pharma got concerned about being left out, they could go hostile. That would give them the software, patents and dosomitry. You would assume that Dr. Lilge and Dr. Jewett could be persuaded with the millions that would be exchanged to see the tech thru.  I have worked for a company that has been bought and sold probably six times over the last thirty years. Most of the expertise transfers with the company especially when the employees just made a ton of money on stock options with the sale.Most takeovers are signed off on by the board of directors but there are times where an acquirer goes straight to the shareholders with a tender. Where I may differ with Bencro, is with all big pharma watching this with big interest, if they got consistent results with 9 patients with no life threatening side effects,no changes in bladder texture or function and efficacious results, I definitely see a possibility that one would try to go early. It would still be a lot cheaper, than waiting for the larger sample. I only suggest this because of the unusual nature of this situation. They all know it would be worth many billions and not one of them would turn down a chance to participate in what could be the ground floor of the future of tumor based oncology. This is all conjecture anyway, Bencro has pointed out that RW would likely stand aside and let a stronger company take the cancer side to the goal line. I stipulate because I could see RW retaining the therapeutic side and growing that division with marketing and targeted studies.
Bullboard Posts